Literature DB >> 19515554

High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985-2005.

Antonio Briccoli1, Michele Rocca, Mariacristina Salone, Gaetano Antonio Guzzardella, Alba Balladelli, Gaetano Bacci.   

Abstract

BACKGROUND: Approximately one-third of patients with localized osteosarcoma at presentation relapse as well as about three-fourths of the patients with metastases at diagnosis, about 90% of relapses are lung metastases. The role of lung metastasectomy remains to be determined. PATIENTS: and methods: Three hundred and twenty three patients, 88 with resectable lung metastases at diagnosis and 235 with localized disease at presentation who relapsed with lung metastases were treated.
RESULTS: A total of 498 lung surgeries and 607 thoracotomies were performed. The 5 year overall survival was 37%. Final outcome was significantly related to presence or absence of metastasis, time of first relapse and presence of local recurrences. According to stage of the disease, the rate of a 5 year event-free survival (EFS) was 36% for patients with localized disease who later relapsed and 9% for patients with resectable lung metastases at presentation (p<0.0001). However, there were no differences in EFS between patients who underwent two or three thoracotomies and patients who had four or five thoracotomies (7.5 vs 18.7%, p=0.29).
CONCLUSIONS: In patients with recurrent resectable pulmonary metastases from high grade osteosarcoma treated with adjuvant or neoadjuvant chemotherapy, thoracotomy should always be considered regardless the number of previous lung relapses and the number of secondary pulmonary lesions.
Copyright © 2009. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 19515554     DOI: 10.1016/j.suronc.2009.05.002

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  61 in total

1.  How far can we go with surgery in metastatic osteosarcoma patients?

Authors:  Cristina Meazza; Paolo Scanagatta; Roberto Luksch; Maura Massimino
Journal:  Med Oncol       Date:  2015-07-25       Impact factor: 3.064

2.  Follow-up of treated osteosarcoma patient.

Authors:  Gisele Eiras Martins; Stela Verzinhasse Perez
Journal:  Acta Ortop Bras       Date:  2012       Impact factor: 0.513

3.  Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma.

Authors:  Jiliang He; Peng Zhang; Qinghu Li; Dongsheng Zhou; Ping Liu
Journal:  Oncol Lett       Date:  2015-11-10       Impact factor: 2.967

4.  Chondroblastic osteosarcoma secondary to fibrosarcoma: A case report and literature review.

Authors:  Yi-Fei Zheng; Jun Lin; Hui-Lin Yang
Journal:  Oncol Lett       Date:  2015-10-12       Impact factor: 2.967

Review 5.  Surgical intervention for pulmonary metastases.

Authors:  Joachim Pfannschmidt; Gerlinde Egerer; Marc Bischof; Michael Thomas; Hendrik Dienemann
Journal:  Dtsch Arztebl Int       Date:  2012-10-05       Impact factor: 5.594

Review 6.  Advancing therapy for osteosarcoma.

Authors:  Jonathan Gill; Richard Gorlick
Journal:  Nat Rev Clin Oncol       Date:  2021-06-15       Impact factor: 66.675

Review 7.  Pulmonary metastasectomy: an overview.

Authors:  Francesco Petrella; Cristina Diotti; Arianna Rimessi; Lorenzo Spaggiari
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 8.  Metastasectomy in pediatric patients: indications, technical tips and outcomes.

Authors:  Paolo Scanagatta; Lara Girelli
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 9.  Survival and prognostic factors following pulmonary metastasectomy for sarcoma.

Authors:  Giuseppe Marulli; Marco Mammana; Giovanni Comacchio; Federico Rea
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

10.  Initial diagnostic management of pediatric bone tumors.

Authors:  Rodrigo B Interiano; Alpin D Malkan; Amos H P Loh; Nathan Hinkle; Fazal N Wahid; Armita Bahrami; Shenghua Mao; Jianrong Wu; Michael W Bishop; Michael D Neel; Robert E Gold; Bhaskar N Rao; Andrew M Davidoff; Israel Fernandez-Pineda
Journal:  J Pediatr Surg       Date:  2016-03-02       Impact factor: 2.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.